Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycystic Ovary Syndrome 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Insulin Resistance 1Inflammation 1Hyperinsulinism 1Breast Neoplasms 1

Interventions

Gemcitabine 6Irinotecan 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Specimen Handling 3Leucovorin 3Fluorouracil 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3palbociclib 2olaparib 2cobimetinib 2Radiosurgery 2Positron-Emission Tomography 2Oncolytic Virotherapy 2Nivolumab 2Ketamine 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Disulfides 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trastuzumab biosimilar HLX02 1toripalimab 1sonidegib 1semaglutide 1pimonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pancreatic Neoplasms × Pioglitazone × Clear all
NCT00867126 2018-11-26

Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine

University of Texas Southwestern Medical Center

Phase EARLY_PHASE1 Terminated
6 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡